^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

Excerpt:
For PFS...Both EGFRvIII expression and PTEN expression were present, but none had 6-month PFS or an objective response...
DOI:
10.1200/JCO.2008.17.5984
Trial ID: